Advertisement

Molecular Diagnosis & Therapy

, Volume 17, Issue 1, pp 49–56 | Cite as

Calprotectin in Rheumatoid Arthritis

Association with Disease Activity in a Cross-Sectional and a Longitudinal Cohort
  • Miriam García-AriasEmail author
  • Dora Pascual-Salcedo
  • Susana Ramiro
  • Marie-Eve Ueberschlag
  • Thomas M. Jermann
  • Carlos Cara
  • Emilio Martín-Mola
  • Alejandro Balsa
Original Research Article

Abstract

Background

Calprotectin is potentially a more sensitive biomarker of disease activity in rheumatoid arthritis (RA) than conventional acute-phase proteins such as the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) because it directly reflects inflammation in the synovium and synovial fluid rather than systemic inflammatory activity.

Objective

The aim of this study was to evaluate relationships between serum calprotectin levels, disease activity, and response to treatment. Calprotectin was also investigated as a predictive marker of clinical response.

Methods

This observational study included selected cohorts of patients with RA treated at La Paz University Hospital, Madrid, Spain. Associations between serum calprotectin levels and clinical and laboratory parameters were analyzed in a cross-sectional cohort of 60 patients with varying disease activity, and changes in calprotectin levels in response to treatment with infliximab were analyzed at baseline and after 3 and 6 months of treatment in a longitudinal cohort of 20 patients with very active disease.

Results

In the cross-sectional cohort, calprotectin levels correlated with rheumatoid factor levels (r = 0.25; p < 0.05) but not with titers of antibodies to cyclic citrullinated peptide. Significant correlations were also observed between calprotectin levels and the 28 swollen joint count (28-SJC), Disease Activity Score based on a 28-joint count (DAS28), Simplified Disease Activity Index (SDAI), ESR, and CRP levels. In the longitudinal cohort, calprotectin levels at baseline were not predictive of response to treatment but significantly decreased during treatment in responders (p < 0.0001).

Conclusion

Calprotectin levels strongly correlate with clinical and laboratory assessments of joint inflammation and also decrease in response to treatment, indicating that calprotectin is a promising marker for assessment and monitoring of disease activity in patients with RA. Investigations are required to further evaluate its diagnostic, prognostic, and therapeutic potential.

Keywords

Infliximab Rheumatoid Arthritis Patient High Disease Activity Simplify Disease Activity Index Calprotectin Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

This work was supported by an unrestricted grant from UCB Pharma (Madrid, Spain). Technical editing and manuscript styling assistance was provided by Andrea Bothwell of inScience Communications, Springer Healthcare, with funding provided by UCB Pharma. Marie-Eve Ueberschlag and Thomas M. Jermann are employees of Bühlmann Laboratories AG (Schönenbuch, Switzerland). Carlos Cara is an employee of UCB Pharma. Alejandro Balsa has received grants and consulting fees/honoraria from UCB Pharma. The authors have no other conflicts of interest that are directly relevant to the content of this article.

References

  1. 1.
    Scott DL, Symmons DP, Coulton BL, et al. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet. 1987;1:1108–11.PubMedCrossRefGoogle Scholar
  2. 2.
    Foell D, Frosch M, Sorg C, et al. Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation. Clin Chim Acta. 2004;344:37–51.PubMedCrossRefGoogle Scholar
  3. 3.
    Nacken W, Roth J, Sorg C, et al. S100A9/S100A8: myeloid representatives of the S100 protein family as prominent players in innate immunity. Microsc Res Tech. 2003;60:569–80.PubMedCrossRefGoogle Scholar
  4. 4.
    Odink K, Cerletti N, Bruggen J, et al. Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis. Nature. 1987;330:80–2.PubMedCrossRefGoogle Scholar
  5. 5.
    Wilkinson MM, Busuttil A, Hayward C, et al. Expression pattern of two related cystic fibrosis-associated calcium-binding proteins in normal and abnormal tissues. J Cell Sci. 1988;91:221–30.PubMedGoogle Scholar
  6. 6.
    Dorin JR, Novak M, Hill RE, et al. A clue to the basic defect in cystic fibrosis from cloning the CF antigen gene. Nature. 1987;326:614–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Fagerhol MK, Dale I, Andersson T, et al. Release and quantitation of a leucocyte derived protein (L1). Scand J Haematol. 1980;24:3913–8.Google Scholar
  8. 8.
    Kane D, Roth J, Frosch M, et al. Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis. Arthritis Rheum. 2003;48:1676–85.PubMedCrossRefGoogle Scholar
  9. 9.
    Vogl T, Ludwig S, Goebeler M, et al. MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. Blood. 2004;104:4260–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Frosch M, Strey A, Vogl T, et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers of monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2000;43:628–37.PubMedCrossRefGoogle Scholar
  11. 11.
    Berntzen HB, Munthe E, Fagerhol MK. A longitudinal study of the leukocyte protein L1 as an indicator of disease activity in patients with rheumatoid arthritis. J Rheumatol. 1989;16:1416–20.PubMedGoogle Scholar
  12. 12.
    Cerezo LA, Mann H, Pecha O, et al. Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. Arthritis Res Ther. 2011;13:R122.CrossRefGoogle Scholar
  13. 13.
    Hammer HB, Fagerhol MK, Wien TN, et al. The soluble biomarker calprotectin (a S100 protein) is associated to ultrasonographic synovitis scores and is sensitive to change in patients with rheumatoid arthritis treated with adalimumab. Arthritis Res Ther. 2011;13:R178.PubMedCrossRefGoogle Scholar
  14. 14.
    Hammer HB, Haavardsholm EA, Kvien TK. Calprotectin (a major leucocyte protein) is associated with the levels of anti-CCP and rheumatoid factor in a longitudinal study of patients with very early rheumatoid arthritis. Scand J Rheumatol. 2008;37:179–82.PubMedCrossRefGoogle Scholar
  15. 15.
    Hammer HB, Odegard S, Fagerhol MK, et al. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Ann Rheum Dis. 2007;66:1093–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Hammer HB, Odegard S, Syversen SW, et al. Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis. Ann Rheum Dis. 2010;69:150–4.PubMedCrossRefGoogle Scholar
  17. 17.
    Berntzen HB, Olmez U, Fagerhol MK, et al. The leukocyte protein L1 in plasma and synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Scand J Rheumatol. 1991;20:74–82.PubMedCrossRefGoogle Scholar
  18. 18.
    Frosch M, Vogl T, Seeliger S, et al. Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2003;48:2622–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Wulffraat NM, Haas PJ, Frosch M, et al. Myeloid related protein 8 and 14 secretion reflects phagocyte activation and correlates with disease activity in juvenile idiopathic arthritis treated with autologous stem cell transplantation. Ann Rheum Dis. 2003;62:236–41.PubMedCrossRefGoogle Scholar
  20. 20.
    Hammer HB, Kvien TK, Glennas A, et al. A longitudinal study of calprotectin as an inflammatory marker in patients with reactive arthritis. Clin Exp Rheumatol. 1995;13:59–64.PubMedGoogle Scholar
  21. 21.
    Ryckman C, Gilbert C, de Medicis R, et al. Monosodium urate monohydrate crystals induce the release of the proinflammatory protein S100A8/A9 from neutrophils. J Leukoc Biol. 2004;76:433–40.PubMedCrossRefGoogle Scholar
  22. 22.
    Ryckman C, McColl SR, Vandal K, et al. Role of S100A8 and S100A9 in neutrophil recruitment in response to monosodium urate monohydrate crystals in the air-pouch model of acute gouty arthritis. Arthritis Rheum. 2003;48:2310–20.PubMedCrossRefGoogle Scholar
  23. 23.
    Haga HJ, Brun JG, Berntzen HB, et al. Calprotectin in patients with systemic lupus erythematosus: relation to clinical and laboratory parameters of disease activity. Lupus. 1993;2:47–50.PubMedGoogle Scholar
  24. 24.
    Rhodes B, Merriman ME, Harrison A, et al. A genetic association study of serum acute-phase C-reactive protein levels in rheumatoid arthritis: implications for clinical interpretation. PLoS Med. 2010;7:e1000341.PubMedCrossRefGoogle Scholar
  25. 25.
    van der Heijde DM, van ‘t Hof MA, van Riel PL, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis. 1990;49:916–20.PubMedCrossRefGoogle Scholar
  26. 26.
    van Gestel AM, Prevoo ML, van ‘t Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39:34–40.PubMedCrossRefGoogle Scholar
  27. 27.
    Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.PubMedCrossRefGoogle Scholar
  28. 28.
    Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003;42:244–57.CrossRefGoogle Scholar
  29. 29.
    Altwegg LA, Neidhart M, Hersberger M, et al. Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes. Eur Heart J. 2007;28:941–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Burkhardt K, Radespiel-Troger M, Rupprecht HD, et al. An increase in myeloid-related protein serum levels precedes acute renal allograft rejection. J Am Soc Nephrol. 2001;12:1947–57.PubMedGoogle Scholar
  31. 31.
    Healy AM, Pickard MD, Pradhan AD, et al. Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation. 2006;113:2278–84.PubMedCrossRefGoogle Scholar
  32. 32.
    Striz I, Jaresova M, Lacha J, et al. MRP 8/14 and procalcitonin serum levels in organ transplantations. Ann Transplant. 2001;6:6–9.PubMedGoogle Scholar
  33. 33.
    Goebeler M, Roth J, Burwinkel F, et al. Expression and complex formation of S100-like proteins MRP8 and MRP14 by macrophages during renal allograft rejection. Transplantation. 1994;58:355–61.PubMedGoogle Scholar
  34. 34.
    Hessian PA, Fisher L. The heterodimeric complex of MRP-8 (S100A8) and MRP-14 (S100A9): antibody recognition, epitope definition and the implications for structure. Eur J Biochem. 2001;268:353–63.PubMedCrossRefGoogle Scholar
  35. 35.
    Zwadlo G, Schlegel R, Sorg C. A monoclonal antibody to a subset of human monocytes found only in the peripheral blood and inflammatory tissues. J Immunol. 1986;137:512–8.PubMedGoogle Scholar
  36. 36.
    Aletaha D, Ward MM, Machold KP, et al. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum. 2005;52:2625–36.PubMedCrossRefGoogle Scholar
  37. 37.
    Leeb BF, Andel I, Sautner J, et al. Disease activity measurement of rheumatoid arthritis: comparison of the Simplified Disease Activity Index (SDAI) and the Disease Activity Score Including 28 Joints (DAS28) in daily routine. Arthritis Rheum. 2005;53:56–60.PubMedCrossRefGoogle Scholar
  38. 38.
    Smolen JS, Aletaha D. Activity assessments in rheumatoid arthritis. Curr Opin Rheumatol. 2008;20:306–13.PubMedCrossRefGoogle Scholar
  39. 39.
    Fransen J, van Riel PL. DAS remission cut points. Clin Exp Rheumatol. 2006;24(6 Suppl 43):S-29–32.Google Scholar
  40. 40.
    Vossenaar ER, Nijenhuis S, Helsen MMA, et al. Citrullination of synovial proteins in murine models of rheumatoid arthritis. Arthritis Rheum. 2003;48:2489–500.PubMedCrossRefGoogle Scholar
  41. 41.
    Bos WH, Bartelds GM, Wolbink GJ, et al. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. J Rheumatol. 2008;35:1972–7.PubMedGoogle Scholar
  42. 42.
    De Rycke L, Verhelst X, Kruithof E, et al. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis. 2005;64:299–302.PubMedCrossRefGoogle Scholar
  43. 43.
    Mikuls TR, O’Dell JR, Stoner JA, et al. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum. 2004;50:3776–82.PubMedCrossRefGoogle Scholar
  44. 44.
    Gebhardt C, Breitenbach U, Tuckermann JP, et al. Calgranulins S100A8 and S100A9 are negatively regulated by glucocorticoids in a c-Fos-dependent manner and overexpressed throughout skin carcinogenesis. Oncogene. 2002;21:4266–76.PubMedCrossRefGoogle Scholar
  45. 45.
    Niu H, Hinkle DA, Wise PM. Dexamethasone regulates basic fibroblast growth factor, nerve growth factor and S100beta expression in cultured hippocampal astrocytes. Brain Res Mol Brain Res. 1997;51:97–105.PubMedCrossRefGoogle Scholar
  46. 46.
    Hsu K, Passey RJ, Endoh Y, et al. Regulation of S100A8 by glucocorticoids. J Immunol. 2005;174:2318–26.PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Miriam García-Arias
    • 1
    Email author
  • Dora Pascual-Salcedo
    • 2
  • Susana Ramiro
    • 2
  • Marie-Eve Ueberschlag
    • 3
  • Thomas M. Jermann
    • 3
  • Carlos Cara
    • 4
  • Emilio Martín-Mola
    • 1
  • Alejandro Balsa
    • 1
  1. 1.Rheumatology UnitLa Paz University HospitalMadridSpain
  2. 2.Immunology UnitLa Paz University HospitalMadridSpain
  3. 3.Bühlmann Laboratories AGSchönenbuchSwitzerland
  4. 4.UCB PharmaMadridSpain

Personalised recommendations